Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL): 4 pipeline candidates · 1 upcoming catalyst · ~3 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.8 months
D/E 0.32 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~125d
N/A
A transparent, data-derived signal for Cardiol Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$122.2M
Cash
$21.4M
Quarterly Burn
$23.9M
Runway
2.8 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Phase 3 |
| CardiolRx | Phase 2 |
| cdr132l | Phase 1 |
| cdr132l | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
44
Total value held
$27.0M
| Holder | Shares | Value |
|---|---|---|
| mmcap international inc. spc | 15,352,317 | $20.7M |
| citadel advisors llc | 896,504 | $1.2M |
| boothbay fund management, llc | 794,881 | $1.1M |
| two sigma investments, lp | 534,211 | $721K |
| integrity alliance, llc. | 465,025 | $630K |
| goldman sachs group inc | 332,400 | $449K |
| morgan stanley | 250,421 | $338K |
| renaissance technologies llc | 229,806 | $310K |
| jane street group, llc | 172,757 | $235K |
| summit financial, llc | 104,059 | $140K |
Showing top 10 of 44 institutional holders of Cardiol Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cardiol Therapeutics Inc.'s pipeline?
Cardiol Therapeutics Inc. (CRDL) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cardiol Therapeutics Inc.'s lead drug candidate?
Cardiol Therapeutics Inc.'s most advanced tracked candidate is Cannabidiol, pharmaceutically produced with < 5 ppm THC (Phase 3) for COVID-19.
What is Cardiol Therapeutics Inc.'s next catalyst?
Cardiol Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controll" — expected October 21, 2026.
What is Cardiol Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cardiol Therapeutics Inc. has approximately 2.8 months of cash runway.
What is Cardiol Therapeutics Inc.'s market capitalization?
Cardiol Therapeutics Inc.'s market capitalization is approximately $122.2M.
Get the full picture on Cardiol Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.